Doctor of Osteopathy Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Eric Goldberg

Psychiatry Destin, FL Doctor of Osteopathy

NPI 1679524946 CMS profile 121350

137 Crystal Beach Dr Ste 137-C, Destin, FL 32541

Open in the dashboard

General payments

$208,038

667 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Eric Goldberg of Destin, FL is reported in the CMS Open Payments database as having received $208,038 across 667 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 98th percentile of Psychiatry profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $118,233 227
2024 General $36,998 102
2023 General $39,164 125
2022 General $7,018 71
2021 General $2,055 75
2020 General $1,386 31
2019 General $3,183 36

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Eric Goldberg
  • Psychiatry median
  • Middle half of Psychiatry
  • National median

In program year 2025, general payments to Eric Goldberg were reported at $118,233. Among 14,155 Psychiatry profiles paid that year, the median was $180 and the middle half received between $58 and $685.

Show as a table
Year Eric Goldberg Psychiatry median Middle half National median
2019 $3,183 $184 $59–$605 $163
2020 $1,386 $119 $36–$372 $114
2021 $2,055 $143 $43–$576 $132
2022 $7,018 $153 $50–$590 $149
2023 $39,164 $170 $56–$651 $160
2024 $36,998 $179 $57–$673 $164
2025 $118,233 $180 $58–$685 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Supernus Pharmaceuticals, Inc. $112,233 146 payments
  2. ITI, Inc. $82,157 198 payments
  3. Sunovion Pharmaceuticals Inc. $3,438 20 payments
  4. US WorldMeds, LLC $2,693 4 payments
  5. AbbVie, Inc. $1,309 70 payments
  6. Janssen Pharmaceuticals, Inc $748 21 payments
  7. Axsome Therapeutics, Inc. $669 21 payments
  8. Lundbeck LLC $421 21 payments
  9. Jazz Pharmaceuticals Inc. $404 16 payments
  10. Novo Nordisk Inc $391 5 payments
  11. Other $3,575 145 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $130,775 59 payments
  2. Honoraria $33,925 14 payments
  3. Travel and Lodging $20,008 76 payments
  4. Food and Beverage $18,049 516 payments
  5. Consulting Fee $5,280 2 payments
Products named General payments · program years 2019–2025
  1. CAPLYTA Psychiatry $80,831 155 payments
  2. Qelbree Viloxazine Hydrochloride $71,602 85 payments
  3. QELBREE Psychology $43,325 65 payments
  4. LATUDA $3,438 20 payments
  5. CAPLYTA Psychiatry $1,325 43 payments
  6. VRAYLAR Neuroscience $1,007 58 payments
  7. Auvelity $669 21 payments
  8. SPRAVATO $574 18 payments
  9. VRAYLAR Neuroscience $418 20 payments
  10. REXULTI $369 18 payments
  11. Other $5,218 197 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 13 drugs

Part D claims

299

Median for Psychiatry: 574

Drug cost

$19,820

Median for Psychiatry: $27,624

Branded share of claims

30.4%

Median for Psychiatry: 17%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Lurasidone Hcl Generic 22 $10,416
Vyvanse Lisdexamfetamine Dimesylate Brand 11 $4,199
Vilazodone Hcl Generic 18 $1,993
Dextroamphetamine-Amphetamine Dextroamphetamine/Amphetamine Brand 56 $1,552
Lamotrigine Generic 36 $344
Escitalopram Oxalate Generic 17 $317
Dextroamphetamine-Amphet Er Dextroamphetamine/Amphetamine Brand 11 $310
Mirtazapine Generic 14 $166
Zolpidem Tartrate Generic 31 $146
Clonazepam Generic 18 $109

The 10 drugs with the highest cost, of 13 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 20,488 Part D prescribers listed as Psychiatry; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 16 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Qelbree
  • Supernus Pharmaceuticals, Inc. $35,360
$35,360 — —
VRAYLAR
  • AbbVie, Inc. $285
$285 — —
CAPLYTA
  • ITI, Inc. $273
$273 — —
Auvelity
  • Axsome Therapeutics, Inc. $224
$224 — —
XYWAV
  • JAZZ PHARMACEUTICALS INC. $173
$173 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 16 in the dashboard with a free account

Records

667 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Psychiatry in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record